市場調査レポート
商品コード
1159353
卵巣がん治療薬の世界市場(2022年~2028年)Ovarian Cancer Drugs Market 2022-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
卵巣がん治療薬の世界市場(2022年~2028年) |
出版日: 2022年10月18日
発行: Orion Market Research
ページ情報: 英文 125 Pages
納期: 2~3営業日
|
世界の卵巣がん治療薬の市場規模は、予測期間中に13.8%の大幅なCAGRで成長すると予測されています。卵巣がん治療に対する意識の高まりと、新興国における医療費の増加が、卵巣がん治療薬市場の成長を後押ししています。医療費の増加は、多くの人々が高度な医療施設を利用できるようにし、ひいては卵巣がんを含む様々ながんの診断と治療に貢献しています。
当レポートでは、世界の卵巣がん治療薬市場について調査し、市場の概要とともに、競合情勢、セグメント別の市場、地域別分析、および企業プロファイルなどを提供しています。
Global Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report by Drug Class (PARP Inhibitors, Angiogenesis Inhibitors, PD-L1 Inhibitors), and by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others) Forecast Period (2022-2028)
The global ovarian cancer drugs market is anticipated to grow at a substantial CAGR of 13.8% during the forecast period. The rising awareness towards the ovarian cancer treatment along with increase in healthcare expenditure in emerging economies is propelling the growth of ovarian cancer drugs market. The increase in expenditure on healthcare is mainly supported by the need among individuals for quality healthcare services. According to the statistics by the World Bank, the current health expenditure (% of GDP) around the world increased from 8.63% in 2000 to 9.84% in 2019. Rising healthcare expenditure is allowing a large number of people to access advanced healthcare facilities, which in turn, is contributing to the diagnosis and treatment of various cancers, including ovarian cancer.
The global Ovarian Cancer Drugs market is segmented based on the drug class, and therapy. Based on the drug class, the market is segmented into PARP inhibitors, angiogenesis inhibitors, and PD-L1 inhibitors. Based on, the therapy the market is sub-segmented into the chemotherapy, targeted therapy, immunotherapy, and others. The above-mentioned segments can be customized as per the requirements. On the basis of drug class, PARP inhibitors are anticipated to be the fastest growing drug class in the ovarian cancer market owing to increasing research and development among major key players to develop new products is anticipated to drive the growth of the market. For instance, in April 2020, the US Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Furthermore, other factors such as increase in demand for PARP inhibitors due to their superior efficacy are likely to boost further market growth.
Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Asia-Pacific is estimated to contribute significantly to the growth of the market. China and India are the major contributors to the growth of the Asia-Pacific ovarian cancer drugs market. The high prevalence and incidence rate of ovarian cancer in China, augments the adoption of drugs and devices for the treatment of ovarian cancer, marking it one of the key factors that drive the market growth. The rising healthcare industry and cancer research institutes along with increasing awareness regarding the treatment procedures of ovarian cancer is further propelling market growth. Additionally, Asia-Pacific comprises approximately 60% of the world population, the region accounts to register a significant proportion in total cases of cancer every year, owing to which, the market for ovarian cancer drugs is growing proportionally in Asia-Pacific.
The major companies serving the global Ovarian Cancer Drugs market include AstraZeneca PLC, Clovis Oncology, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In 2020, AstraZeneca and MSD Inc announced that Lynparza*(Olaparib) in combination with bevacizumab has been approved in the US for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
Research Methodology
The market study of the global ovarian cancer drugs market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers: